Review decision – July 2018

Decision to incorporate into an ongoing update of a NICE clinical guideline and transferred to the static list.

We would like to update you on the decision made regarding the review of the existing guidance on TA388: sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction.

TA388 makes an optimised recommendation for sacubitril valsartan in people already receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) with NYHA class II–IV symptoms, and a left ventricular ejection fraction (LVEF) of 35% or less. Relevant trials identified since TA388 may address some of the uncertainties identified in the appraisal, but are unlikely to change the recommendation in the original guidance.

NICE is updating CG108 to produce a new guideline on chronic heart failure; this guidance is expected to be published in August 2018. The final scope for CG108 (published April 2016) includes updates to the guidelines on pharmacological therapies for managing chronic heart failure. Because TA388 is directly related to this guideline review question, it is proposed that the appraisal is incorporated into this guideline and transferred to the static list.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently, TA388 will move to the ‘static list’ of technology appraisals.

Review decision paper


This page was last updated: